Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.02.15.22270948: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The national and the institutional review board approved the protocol and the consent forms.
Consent: The national and the institutional review board approved the protocol and the consent forms.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources SARS-CoV-2 IgG II Quant (Abbott, IL, USA), (ii) SARS-CoV-2 pseudovirus neutralization assay using a vesicular stomatitis virus (VSV) backbone coated with SARS-CoV-2 spike (S) protein (ref), (iii) Live microneutralization of different strains; Wu-1 as well as Alpha, Delta and Omicron VOCs 15 Abbottsuggested: (Abbott, RRID:SCR_0…SciScore for 10.1101/2022.02.15.22270948: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The national and the institutional review board approved the protocol and the consent forms.
Consent: The national and the institutional review board approved the protocol and the consent forms.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources SARS-CoV-2 IgG II Quant (Abbott, IL, USA), (ii) SARS-CoV-2 pseudovirus neutralization assay using a vesicular stomatitis virus (VSV) backbone coated with SARS-CoV-2 spike (S) protein (ref), (iii) Live microneutralization of different strains; Wu-1 as well as Alpha, Delta and Omicron VOCs 15 Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has several limitations. First, this was not a randomized placebo-controlled trial, since it was primarily designed to assess immunogenicity, which should not be affected by our study design. However, generating potential biases in assessing vaccine efficacy. To overcome these, we compared each intervention group separately to an age-matched 2:1 control group. Second, the two intervention arms were initiated with a one week difference, leading to two potential biases; time dependent, due to the rapid surge during the study period, and minor difference in the population baseline characteristics of each arm (e.g., slightly younger in the mRNA1273 cohort). These potential biases were addressed by using a Poisson model accounting for calendar time and age. While we did not find a significant difference between the two mRNA vaccines, this is an interim report, and differences in durability of the vaccine effects may be identified only with future follow up. Finally, our study is relatively small, and thus wide confidence intervals for vaccine efficacy are reported. Our data provides evidence that an mRNA fourth vaccine dose is immunogenic, safe and somewhat efficacious, apparently more against symptomatic disease. Four to five months after the third dose, the fourth dose increases immunogenicity and restores it to levels comparable to peak antibody levels after the third vaccine dose. Thus, while mRNA vaccines seem to be highly potent and protective against severe diseas...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT05231005 Active, not recruiting Fourth BNT162b2 COVID-19 Vaccine Dose NCT05230953 Active, not recruiting Fourth COVID-19 Vaccine Dose- mRNA1273 Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
